Rob M Kok1, Willem A Nolen, Thea J Heeren. 1. Department of Old Age Psychiatry, Altrecht Institute of Mental Health Care, Utrecht, The Netherlands. r.kok@altrecht.nl
Abstract
BACKGROUND: The majority of the trials in the elderly are outpatient trials which excluded psychotic patients and patients with common comorbid physical disorders. Consequently information is lacking about the more complex cases of elderly depressed patients, as found in inpatient wards. OBJECTIVE: To evaluate the effectiveness of two antidepressants, venlafaxine and nortriptyline, in a clinically representative sample of elderly depressed inpatients. METHOD: A 12-week, double blind, randomised, controlled trial in 81 elderly inpatients from one centre. All patients fulfilled DSM-IV criteria for major depression and were assessed using the Montgomery Asberg Depression Rating Scale, the Hamilton Depression Rating Scale, the Geriatric Depression Scale, the Clinical Global Improvement and the Symptom, sign, and Side-effect Checklist. RESULTS:Overall, remission was achieved by 26 (32.1%) of the patients. There was no statistically significant difference in the number of patients achieving remission on the MADRS between venlafaxine (11 out of 40 patients) and nortriptyline (15 out of 41 patients; p = 0.381) or in any of the secondary outcome variables. The number and severity of side-effects was not statistically different between both treatment groups and most side effects were mild or moderate in intensity. CONCLUSIONS: In elderly inpatients with severe depression, venlafaxine and nortriptyline appeared to be equally effective and equally well tolerated.
RCT Entities:
BACKGROUND: The majority of the trials in the elderly are outpatient trials which excluded psychoticpatients and patients with common comorbid physical disorders. Consequently information is lacking about the more complex cases of elderly depressed patients, as found in inpatient wards. OBJECTIVE: To evaluate the effectiveness of two antidepressants, venlafaxine and nortriptyline, in a clinically representative sample of elderly depressed inpatients. METHOD: A 12-week, double blind, randomised, controlled trial in 81 elderly inpatients from one centre. All patients fulfilled DSM-IV criteria for major depression and were assessed using the Montgomery Asberg Depression Rating Scale, the Hamilton Depression Rating Scale, the Geriatric Depression Scale, the Clinical Global Improvement and the Symptom, sign, and Side-effect Checklist. RESULTS: Overall, remission was achieved by 26 (32.1%) of the patients. There was no statistically significant difference in the number of patients achieving remission on the MADRS between venlafaxine (11 out of 40 patients) and nortriptyline (15 out of 41 patients; p = 0.381) or in any of the secondary outcome variables. The number and severity of side-effects was not statistically different between both treatment groups and most side effects were mild or moderate in intensity. CONCLUSIONS: In elderly inpatients with severe depression, venlafaxine and nortriptyline appeared to be equally effective and equally well tolerated.
Authors: Eric J Lenze; Benoit H Mulsant; Daniel M Blumberger; Jordan F Karp; John W Newcomer; Stewart J Anderson; Mary Amanda Dew; Meryl A Butters; Jacqueline A Stack; Amy E Begley; Charles F Reynolds Journal: Lancet Date: 2015-09-27 Impact factor: 79.321
Authors: Charles H Kellner; Mustafa M Husain; Rebecca G Knapp; W Vaughn McCall; Georgios Petrides; Matthew V Rudorfer; Robert C Young; Shirlene Sampson; Shawn M McClintock; Martina Mueller; Joan Prudic; Robert M Greenberg; Richard D Weiner; Samuel H Bailine; Peter B Rosenquist; Ahmad Raza; Styliani Kaliora; Vassilios Latoussakis; Kristen G Tobias; Mimi C Briggs; Lauren S Liebman; Emma T Geduldig; Abeba A Teklehaimanot; Sarah H Lisanby Journal: Am J Psychiatry Date: 2016-07-15 Impact factor: 18.112
Authors: Alisson Paulino Trevizol; Kyle W Goldberger; Benoit H Mulsant; Tarek K Rajji; Jonathan Downar; Zafiris J Daskalakis; Daniel M Blumberger Journal: Int J Geriatr Psychiatry Date: 2019-04-08 Impact factor: 3.485
Authors: Debby L Gerritsen; Martin Smalbrugge; Steven Teerenstra; Ruslan Leontjevas; Eddy M Adang; Myrra J F J Vernooij-Dassen; Els Derksen; Raymond T C M Koopmans Journal: BMC Psychiatry Date: 2011-05-20 Impact factor: 3.630
Authors: Eric J Lenze; Meera Sheffrin; Henry C Driscoll; Benoit H Mulsant; Bruce G Pollock; Mary Amanda Dew; Frank Lotrich; Bernie Devlin; Robert Bies; Charles F Reynolds Journal: Dialogues Clin Neurosci Date: 2008 Impact factor: 5.986